Overview
Corporate ProfileOur success is supported by a proven strategy of marketing high-growth, innovative products, building our marketing and distribution channels, and investing in unique compounds that may change the course of disease. Our strategy balances the risk in our business and further distinguishes Cephalon from the majority of its peers. 
 |
|
| Date | Title | | | 11/05/09 | Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma| FRAZER, Pa., Nov. 5 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab. Results of this study, which supported the FDA approval of TREANDA in this patient population in October 2008, were publishe... |
|  | | 11/04/09 | Cephalon, Inc. to Webcast R&D Day| FRAZER, Pa., Nov. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its Research and Development Day in New York City, to be held on November 10, 2009, will be webcast live on the investor relations section of its website at http://www.cephalon.com.
Cephalon's senior management will review the company's product pipeline and discuss research and development initiatives including its pipeline of biologics from its recent acquisition of Arana Therapeutics. In addit... |
| | | 11/02/09 | Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder| FRAZER, Pa., Nov. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD). NUVIGIL, the longer-lasting isomer of modafinil, is indicated to improve wakefulness in patients with excessive ... |
| | | 10/27/09 | Cephalon Net Sales Increase 9% and Net Cash from Operations Surpasses $200 Million in the Third Quarter 2009| Adjusted Net Income Surpasses Guidance
FRAZER, Pa., Oct. 27 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2009 net sales of $535.2 million, a 9 percent increase compared to net sales of $489.7 million for the third quarter 2008. Basic income per common share for the quarter was $1.38. Excluding amortization expense and certain other items, basic adjusted income per common share for the quarter was $1.70, an increase of 25 percent over the compara... |
| |
|
|
| There are currently no events scheduled. |
Print Page | 
Email Page | 
RSS Feeds | 
Financial Tear Sheet